BioRestorative Therapies, Inc. short interest in 2023
In 2023, BioRestorative Therapies, Inc.'s disclosed short interest ran from 1.47% of shares outstanding on 13 Jan 2023 to 0.38% on 29 Dec 2023, a change of -1.09 percentage points. The year's high was 2.85% on 15 Mar 2023 and its low 0.38% on 29 Dec 2023, averaging 1.35% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.43 days on 31 Jan 2023. Full history: BioRestorative Therapies, Inc..
Cite this page
By year: 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 1.47% (13 Jan 2023)
- End of year
- 0.38% (29 Dec 2023)
- Change
- -1.09 pp
- High
- 2.85% (15 Mar 2023)
- Low
- 0.38% (29 Dec 2023)
- Average
- 1.35%
- Highest days to cover
- 9.43 (31 Jan 2023)
- SEC filings marked
- 4
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 1.47% | 5.68 | |
| 31 Jan 2023 | 1.30% | 9.43 | |
| 15 Feb 2023 | 1.23% | 3.65 | |
| 28 Feb 2023 | 1.23% | 8.71 | |
| 15 Mar 2023 | 2.85% | 1.00 | |
| 31 Mar 2023 | 2.41% | 3.68 | 10-K filed |
| 14 Apr 2023 | 1.92% | 5.90 | |
| 28 Apr 2023 | 1.97% | 3.88 | |
| 15 May 2023 | 1.64% | 1.98 | 10-Q filed |
| 31 May 2023 | 1.72% | 3.00 | |
| 15 Jun 2023 | 1.83% | 6.37 | |
| 30 Jun 2023 | 2.14% | 1.00 | |
| 14 Jul 2023 | 1.26% | 1.00 | |
| 31 Jul 2023 | 1.78% | 1.00 | |
| 15 Aug 2023 | 0.76% | 1.85 | 10-Q filed |
| 31 Aug 2023 | 0.53% | 1.24 | |
| 15 Sep 2023 | 0.42% | 1.00 | |
| 31 Oct 2023 | 1.00% | 2.23 | |
| 15 Nov 2023 | 0.66% | 2.10 | 10-Q filed |
| 30 Nov 2023 | 0.49% | 2.33 | |
| 15 Dec 2023 | 0.80% | 1.96 | |
| 29 Dec 2023 | 0.38% | 1.00 |
See also: BioRestorative Therapies, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.